Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Medistim ASA
F:MD1

Watchlist Manager
Medistim ASA Logo
Medistim ASA
F:MD1
Watchlist
Price: 18.8 EUR -1.83% Market Closed
Market Cap: €344.3m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
+33%
5Y
+46%
10Y
+186%
Liabilities
+
3Y
+81%
5Y
+63%
10Y
+168%
Equity
+
3Y
+21%
5Y
+40%
10Y
+193%

Balance Sheet Decomposition
Medistim ASA

Balance Sheet
Medistim ASA

Rotate your device to view
Balance Sheet
Currency: NOK
Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
12
5
27
21
16
16
27
29
35
29
27
20
49
49
31
54
47
67
72
129
144
154
179
Cash
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
144
0
0
Cash Equivalents
12
5
27
21
16
16
27
29
35
29
27
20
49
49
31
54
47
67
72
129
0
154
179
Short-Term Investments
0
0
0
0
0
0
0
5
2
0
1
0
0
0
0
0
0
0
0
0
0
0
0
Total Receivables
8
13
16
20
33
27
33
30
31
33
35
47
50
45
48
56
71
62
61
80
114
88
84
Accounts Receivables
7
12
14
17
26
22
24
23
26
27
30
39
40
45
48
56
71
62
57
69
102
74
69
Other Receivables
1
1
1
3
7
6
9
7
6
5
5
8
10
0
0
0
0
0
4
11
13
13
15
Inventory
11
12
15
14
21
22
25
28
29
32
36
38
37
47
59
63
64
90
113
97
114
145
161
Other Current Assets
1
1
0
1
0
0
0
0
0
0
0
0
0
9
8
6
8
9
0
0
13
12
14
Total Current Assets
32
31
58
55
70
66
85
93
97
94
99
105
135
150
147
179
190
229
246
306
386
392
429
PP&E Net
6
5
5
7
7
7
8
6
5
10
11
14
15
14
18
26
32
65
65
59
51
57
73
PP&E Gross
6
5
5
7
7
7
8
6
5
10
11
14
15
14
18
26
32
65
65
59
51
57
73
Accumulated Depreciation
4
5
7
9
11
13
15
18
20
23
26
28
32
37
41
46
52
64
79
96
113
133
156
Intangible Assets
0
0
0
3
8
11
16
19
20
22
21
30
35
37
34
28
26
24
19
16
22
31
45
Goodwill
9
8
7
8
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
Note Receivable
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
5
2
2
4
6
6
4
Long-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
1
1
2
13
20
30
22
13
9
10
7
6
4
4
3
3
2
3
1
3
4
5
9
Other Assets
9
8
7
8
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
14
Total Assets
47
N/A
45
-4%
71
+57%
85
+20%
119
+40%
129
+8%
145
+13%
146
+0%
146
+0%
150
+3%
152
+2%
168
+11%
203
+21%
219
+8%
217
-1%
251
+16%
270
+7%
336
+25%
346
+3%
403
+17%
483
+20%
506
+5%
575
+14%
Liabilities
Accounts Payable
8
7
5
6
16
9
15
13
10
7
8
10
8
13
8
14
12
15
14
13
24
25
18
Accrued Liabilities
2
2
2
7
0
0
0
0
0
0
7
7
10
11
12
11
16
19
12
22
26
17
24
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
7
5
4
5
3
9
10
7
7
8
9
Other Current Liabilities
13
5
10
2
10
10
20
12
16
22
17
22
26
27
24
28
25
29
24
35
43
44
56
Total Current Liabilities
22
15
16
15
26
19
35
25
26
29
33
39
51
56
48
58
55
71
59
78
100
94
107
Long-Term Debt
9
7
0
1
16
11
7
3
0
0
0
5
11
6
2
11
8
27
29
17
10
9
25
Other Liabilities
1
1
1
2
3
5
8
12
12
14
4
3
0
1
1
0
0
1
0
3
5
4
6
Total Liabilities
31
N/A
22
-29%
17
-23%
18
+3%
45
+156%
35
-22%
50
+43%
39
-21%
38
-3%
43
+12%
37
-14%
47
+28%
64
+38%
63
-2%
50
-20%
68
+35%
63
-8%
99
+58%
89
-10%
97
+9%
115
+18%
108
-6%
138
+28%
Equity
Common Stock
3
4
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
Retained Earnings
7
6
9
21
28
47
49
60
61
61
69
75
93
109
118
134
157
186
205
246
303
327
364
Additional Paid In Capital
6
13
40
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
42
Treasury Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
1
2
3
4
4
6
13
19
25
26
Total Equity
16
N/A
23
+42%
54
+133%
67
+25%
74
+10%
94
+27%
96
+2%
106
+11%
108
+1%
107
-1%
115
+8%
122
+6%
139
+14%
156
+12%
167
+7%
183
+10%
207
+13%
237
+15%
257
+8%
306
+19%
368
+20%
398
+8%
437
+10%
Total Liabilities & Equity
47
N/A
45
-4%
71
+57%
85
+20%
119
+40%
129
+8%
145
+13%
146
+0%
146
+0%
150
+3%
152
+2%
168
+11%
203
+21%
219
+8%
217
-1%
251
+16%
270
+7%
336
+25%
346
+3%
403
+17%
483
+20%
506
+5%
575
+14%
Shares Outstanding
Common Shares Outstanding
13
16
19
19
19
19
19
18
19
19
18
18
18
18
18
18
18
18
18
18
18
18
18

See Also

Summary
MD1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
MD1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MD1 stock valuation using valuation multiples.
Wall Street Estimates
MD1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MD1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 315,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.